CytoDyn presented new preclinical data at the AACR Special Conference in Cancer Research: Brain Cancer in Philadelphia, demonstrating that its lead monoclonal antibody, leronlimab, enhances the killing of glioblastoma multiforme cells when combined with temozolomide or radiation.
The data were presented by Ritika Harish on March 23 2026 and showed that leronlimab’s inhibition of CCR5 increases tumor cell death in combination with standard‑of‑care therapies, providing evidence of synergy in a highly aggressive brain tumor.
"Our findings show that CCR5 expression correlates with glycolytic and hypoxic tumor core signatures, as well as markers of T‑cell exhaustion. Importantly, CCR5 inhibition with leronlimab enhanced tumor cell killing when combined with temozolomide or radiation, support further clinical evaluation of leronlimab as a potential adjunct to standard‑of‑care therapy in glioblastoma." – Professor Richard Pestell, M.D., Ph.D., FRCP, AO, Lead Consultant in Preclinical and Clinical Oncology at CytoDyn.
"These data outline a potential role for CCR5 in glioblastoma, where resistance to standard therapies remains a major unmet need. The observed synergy with temozolomide or radiation, combined with its association with immunosuppressive tumor core signatures, supports current plans to initiate a pilot study evaluating leronlimab in glioblastoma." – Dr. Jacob Lalezari, M.D., Chief Executive Officer of CytoDyn.
The findings support a planned pilot study and add to CytoDyn’s oncology portfolio, which already includes metastatic triple‑negative breast cancer and colorectal cancer. The data also provide a scientific rationale for a prospective clinical trial, a key step toward potential approval and commercialization of leronlimab in oncology.
CytoDyn closed a $17.5 million financing on March 5 2026, providing funding to support operations into 2027 and enabling the company to pursue the glioblastoma program.
The preclinical results represent a material operational milestone that could influence CytoDyn’s clinical development roadmap and future regulatory submissions, underscoring the company’s progress toward expanding its therapeutic portfolio into a disease area with limited treatment options.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.